Abstract

Abstract

Early markers are needed for more effective prevention of Alzheimer’s disease. We previously showed that individuals with Alzheimer’s disease have decreased plasma DYRK1A levels compared to controls. We assessed DYRK1A in the plasma of cognitively healthy elderly volunteers, individuals with either Alzheimer’s disease (AD), tauopathies or Down syndrome (DS), and in lymphoblastoids from individuals with DS. DYRK1A levels were inversely correlated with brain amyloid β burden in asymptomatic elderly individuals and AD patients. Low DYRK1A levels were also detected in patients with tauopathies. Individuals with DS had higher DYRK1A levels than controls, although levels were lower in individuals with DS and with dementia. These data suggest that plasma DYRK1A levels could be used for early detection of at risk individuals of AD and for early detection of AD. We hypothesize that lack of increase of DYRK1A at middle age (40–50 years) could be a warning before the cognitive decline, reflecting increased risk for AD.

Details

Title
Increased plasma DYRK1A with aging may protect against neurodegenerative diseases
Author
Delabar, Jean M. 1   VIAFID ORCID Logo  ; Lagarde, Julien 2   VIAFID ORCID Logo  ; Fructuoso, Marta 1 ; Mohammad, Ammara 1 ; Bottlaender, Michel 3 ; Doran, Eric 4 ; Lott, Ira 4 ; Rivals, Isabelle 5   VIAFID ORCID Logo  ; Schmitt, Frederic A. 6 ; Head, Elizabeth 7 ; Sarazin, Marie 2   VIAFID ORCID Logo  ; Potier, Marie-Claude 1   VIAFID ORCID Logo 

1  Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris Brain Institute (ICM), Centre National de la Recherche Scientifique (CNRS) UMR 7225, INSERM U1127, Paris, France (GRID:grid.411439.a) (ISNI:0000 0001 2150 9058) 
2  Hôpital Sainte Anne, Department of Neurology of Memory and Language, GHU Paris Psychiatrie & Neurosciences, Paris, France (GRID:grid.414435.3) (ISNI:0000 0001 2200 9055); Paris-Saclay University, BioMaps, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, Orsay, France (GRID:grid.414435.3) 
3  Paris-Saclay University, BioMaps, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, Orsay, France (GRID:grid.411439.a) 
4  University of California, School of Medicine, Department of Pediatrics, Irvine, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243) 
5  PSL Research University, Equipe de Statistique Appliquée, ESPCI Paris, INSERM, UMRS 1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France (GRID:grid.440907.e) (ISNI:0000 0004 1784 3645) 
6  University of Kentucky, Department of Neurology, Lexington, USA (GRID:grid.266539.d) (ISNI:0000 0004 1936 8438) 
7  University of Kentucky, Department of Neurology, Lexington, USA (GRID:grid.266539.d) (ISNI:0000 0004 1936 8438); University of California, Department of Pathology and Laboratory Medicine, Irvine, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243) 
Pages
111
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
21583188
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41398-023-02419-0
ProQuest document ID
2795095235
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.